A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine)

The discovery of purine nucleoside phosphorylase (PNP) deficiency and T lymphocytopenia suggested that inhibition of this enzyme could serve as a therapeutic target. Inhibitors of PNP failed until structure-based synthesis of immucillin-H (BCX-1777, forodesine), a transition-state analog of PNP. The...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Gandhi, Varsha, Kilpatrick, John M., Plunkett, William, Ayres, Mary, Harman, Leigh, Du, Min, Bantia, Shanta, Davisson, Jan, Wierda, William G., Faderl, Stefan, Kantarjian, Hagop, Thomas, Deborah
Format: Artigo
Idioma:Inglês
Publicat: © 2005 by The American Society of Hematology 2005
Matèries:
Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895256/
https://ncbi.nlm.nih.gov/pubmed/16131572
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2005-03-1309
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars